Clinical trials located in

Paris

Paris city is located in France. Currently, 20 clinical trials are being conducted in this city.

Paris, France’s capital, is a major European city and a global center for art, fashion, gastronomy, and culture. Its 19th-century cityscape is crisscrossed by wide boulevards and the River Seine. Beyond such landmarks as the Eiffel Tower and the 12th-century, Gothic Notre-Dame cathedral, the city is known for its cafe culture and designer boutiques along the Rue du Faubourg Saint-Honoré. Paris is also renowned for its museums and cultural institutions, including the Louvre, which houses thousands of works of art, making it the world’s largest art museum. The city’s literary history is vibrant, having been home to countless writers and intellectuals. Paris’ influence in politics, education, entertainment, media, fashion, science, and the arts all contribute to its status as one of the world’s major cities.

  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • CT-EU-00084342

    Efficacy and safety of MK-7684A and drug combinations in the treatment of selected malignancies in patients with advanced tumors

    The clinical trial covers various types of cancer such as cervical cancer, endometrial cancer (lining of the uterus), head and neck cancer, gallbladder cancer, cholangiocarcinoma, esophageal cancer, triple negative breast cancer, hepatocellular carcinoma, bladder cancer urinary tract, ovarian cancer and stomach cancer.

    The study is testing various therapies combining pembrolizumab and vibostolimab (designated MK-7684A), pembrolizumab alone and combinations with other anticancer drugs such as lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine and oxaliplatin.

    The aim of the study is to determine the safety, tolerability and preliminary effectiveness of various drug combinations in the treatment of selected advanced malignancies

    • Pembrolizumab
    • Pembrolizumab and Vibostolimab/ MK-7684A
    • Lenvatinib
    • Bevacizumab
    • Gemcitabine
    • Cisplatin
    • Carboplatin
    • Capecitabine
    • Oxaliplatin
    • 5-Fluorouracil
    • Paclitaxel
    • Docetaxel
  • Study of Aplitabart alone or with other treatments in patients with various cancers

    This clinical trial concerns various cancers including solid tumors, colorectal cancer, non-Hodgkin lymphoma, sarcoma, chondrosarcoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

    The main focus of this study is the investigation of a drug called aplitabart (IGM-8444). This drug will be tested alone and in combination with other medications, which include FOLFIRI (a combination chemotherapy regimen), bevacizumab (a targeted therapy also known as Avastin), birinapant (an investigational drug), venetoclax (a targeted therapy also known as Venclexta), docetaxel (a chemotherapy drug also known as Taxotere or Docefrez), gemcitabine (a chemotherapy drug also known as Gemzar), and azacitidine (a chemotherapy drug also known as VIDAZA). The purpose of the study is to determine the safety, tolerability, and how the body processes (pharmacokinetics) aplitabart when used alone or combined with these other drugs.

    There are two main parts of the study. Phase 1a consists of two stages: Dose escalation, where participants will receive increasing doses of aplitabart to determine the safest and most effective dose, and Expansion, where more participants will receive the best dose to see how well it works alone or with other drugs. Phase 1b will focus on colorectal cancer participants. It will be an open-label, randomized study where some participants will receive a combination of aplitabart, FOLFIRI, and bevacizumab, while others will receive only FOLFIRI and bevacizumab.

    All medications will be given intravenously (through a vein). Different tumor types will be included, such as various solid tumors, colorectal cancers, certain types of leukemia, and lymphomas.

    • Aplitabart (IGM-8444)
    • azacitidine
    • Bevacizumab (and approved biosimilars)
    • Birinapant
    • FOLFIRI
    • Gemcitabine
    • Venetoclax
    • Docetaxel
  • Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • Study on the effectiveness and safety of DMX-200 for FSGS patients using ARB

    Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease where some parts of the kidneys become scarred, leading to kidney damage and protein loss in urine. This study involves a therapy using an experimental drug named DMX-200 (also known as repagermanium), which, when taken with a type of medication called an Angiotensin II Receptor Blocker (ARB), aims to halt the inflammation that contributes to chronic kidney disease.

    The study is designed to assess how well DMX-200 works and how safe it is in treating people with FSGS. It will compare the effects of DMX-200 with a placebo over a period of 104 weeks (about 2 years). Patients will be given either DMX-200 in capsule form to take twice daily or a placebo. Given the rarity of FSGS, the study will include both adults and adolescents aged 12 to 17 years.

    The study will start with a screening period to ensure all necessary assessments are completed. This will be followed by the main treatment phase, lasting 104 weeks. After this, there will be a 4-week follow-up period without treatment to observe any changes. Patients who complete this double-blind period and might benefit from continued treatment will enter an open-label extension phase. During this phase, participants will receive DMX-200 for an additional 2 years, also followed by a 4-week off-treatment period for further observation.

    The goal is to determine the effectiveness and long-term safety of DMX-200 for treating FSGS. The study aims to improve understanding and develop new treatments for this challenging kidney condition.

    • DMX-200
    • placebo
  • Studying the safety of a new medicine in treating Primary biliary cholangitis (PBC)

    The study is aimed at patients suffering from primary biliary cholangitis (PBC), a disease causing inflammation and narrowing of the bile ducts. The therapy involves the administration of the drug A3907, also known as Ritivixibat.

    The main goal of the study is to evaluate how safe and well-tolerated A3907 is in individuals with PBC. Additionally, doctors will examine how participants’ bodies respond to the drug and what changes occur during treatment.

    Adults aged 18 to 75 with clinical symptoms of PBC for at least six months can participate. The study includes various dosing groups of A3907 to understand which dose is most effective and safe.

    An important aspect of the study is that participants must be clinically stable for at least three months prior to its commencement. Women of childbearing age must use appropriate contraceptive methods, and all participants must be willing to sign informed consent.

    The study does not include individuals with other chronic liver diseases, including cirrhosis, or those who have had liver transplants or other internal organ surgeries in the past.

  • Study on the use of Volixibat for the treatment of pruritus in patients with primary cholangitis (PBC)

    The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational drug called volixibat in patients with pruritus caused by primary cholangitis. The study aims to understand how volixibat affects the treatment of pruritus associated with this disease and to evaluate its possible effect on disease progression.

    Study participants will be randomly assigned to a group receiving volixibat or placebo. Volixibat will be administered as oral capsules twice daily. The main goal of the study is to measure the average change in daily pruritus scores using a special Adult Itch Reported Outcome (Adult ItchRO) questionnaire. Adult ItchRO is an 11-point scale for assessing pruritus severity, where 0 means no pruritus and 10 means the worst possible pruritus. The study will run from baseline to week 28.

    • Volixibat
    • Placebo
  • Study of Elafibranor in the treatment of adult patients with Primary Biliary Cholangitis (PBC)

    The clinical trial is aimed at adult patients with confirmed primary cholangitis (PBC). Patients with this condition have an inadequate response or intolerance to ursodeoxycholic acid (UDCA), a drug used to treat PBC.

    Primary cholangitis is a disease that slowly progresses and leads to damage to the bile ducts in the liver. This causes a build-up of bile acids, which further damages the liver. As the disease progresses, scarring of the liver may develop (cirrhosis). PBC is also associated with numerous symptoms, such as itching and fatigue, and may lead to the need for a liver transplant.

    The study evaluates the effectiveness and safety of a drug called elafibranor at a dose of 80 mg daily. The study will compare elafibranor with a placebo, an inactive substance administered for control purposes. The main goal of the study is to test the effectiveness of elafibranor. The safety of long-term use of this medicine and its effect on symptoms such as itching and fatigue will also be checked.

    • Elafibranor
  • Study on safety and tolerability of GS030 Gene Therapy for Retinitis Pigmentosa

    This study is designed to help individuals with a specific type of genetic eye disease called non-syndromic Retinitis Pigmentosa. This condition causes the cells in the retina that detect light to gradually stop working, leading to vision loss. The study will focus on a new gene therapy named GS030-DP and a medical device called GS030-MD.

    The purpose of the study is to evaluate the safety and tolerability of different doses of GS030-DP. This therapy involves a single injection into the eye and uses light stimulation with special glasses (GS030-MD).

    The study is divided into different phases to test the therapy’s effects. Initially, three small groups of participants will receive increasing doses of the gene therapy to determine the safest and most effective dose. Following this, another group will receive the highest well-tolerated dose to further confirm its safety and effect.

    Participants in this trial must have confirmed non-syndromic Retinitis Pigmentosa and will be monitored for any side effects and changes in their vision over time. This will help determine how well the new therapy works and if it improves their vision or quality of life.

    • GS030-DP
  • Study on the safety of SPVN06 Gene Therapy for Patients with Advanced Retinitis Pigmentosa

    Rod-Cone Dystrophy is a genetic eye disorder that can lead to severe vision loss. This study is focused on people with advanced Rod-Cone Dystrophy caused by specific gene mutations in RHO, PDE6A, or PDE6B. These genes play a crucial role in the health of the eye’s photoreceptor cells, which are responsible for capturing light and enabling vision.

    The therapy being tested in this study is called SPVN06. This is a gene therapy designed to correct or replace the faulty gene causing the disease. Gene therapy involves introducing a functioning version of a gene to help the body create the proteins it needs to work correctly.

    The main aim of this study is to assess the safety and tolerability of a single injection of SPVN06 in patients with advanced stages of Rod-Cone Dystrophy.

    The study is divided into two steps:
    1. Step 1: This initial phase involves three groups of participants who will receive different doses of SPVN06 to find the appropriate dose.
    2. Step 2: In this phase, participants will be divided into three groups. Two groups will receive the recommended doses identified in Step 1, while the third group will not receive any treatment.

    Throughout the study, participants will be closely monitored for any side effects and their overall health and vision will be regularly checked. The goal is to gather enough data to determine whether SPVN06 is safe to use and if it can help improve vision in people affected by this genetic disorder.

    • SPVN06
  • Study of REGN7257 for patients with severe aplastic anemia not responding to Immunosuppressive Therapy


    This clinical trial focuses on severe aplastic anemia (SAA), a condition where the bone marrow cannot produce enough blood cells. The experimental drug being studied is called REGN7257. The aim is to check if this drug is safe and tolerable in patients with SAA that have not responded to other treatments.

    The study is divided into two parts: Part A and Part B. In Part A, patients will receive a single dose of REGN7257 to find the right dose. Once a safe dose is identified, Part B will involve multiple doses to study the drug’s long-term effects.

    The research will observe any side effects, understand how much of the drug is in the blood over time, and check if the drug helps increase blood counts like red and white blood cells and platelets. Additionally, it will look at whether REGN7257 reduces the need for blood transfusions and changes the level of immune cells in the body.


    • REGN7257
  • Study on Alogabat for Children and Teens with Angelman Syndrome

    This study is investigating a medication called Alogabat for children and adolescents aged 5-17 years who have Angelman Syndrome with a specific genetic deletion. The research will explore how different doses of Alogabat affect the body by measuring its concentration over time and observing any changes in brain activity and safety outcomes. The study includes several phases where doses are adjusted based on early results. This research aims to determine Alogabat’s effectiveness in treating symptoms of Angelman Syndrome in younger populations.

    • Alogabat
  • Study of infigratinib in children with achondroplasia

    The clinical study involves children with achondroplasia who previously participated in the PROPEL study. The study evaluates infigratinib, an oral tablet medication. The goal is to assess the safety, tolerance, and effectiveness of the drug. Infigratinib targets the fibroblast growth factor receptor (FGFR), which is crucial in processes like cell growth, wound healing, and bone and blood vessel formation.

    The study is aimed at children aged 3 to 11 years who can walk unaided and take oral medication. Various doses will be adjusted based on the child’s weight. The study will assess changes in annual height growth, pharmacokinetic parameters (such as maximum drug concentration in the blood), and any adverse events. Additionally, changes in body proportions, limb length, and other growth measures will be analyzed.

    • Infigratinib
  • Study of R3R01 for Kidney Conditions: Alport Syndrome and FSGS

    This study focuses on treating Alport Syndrome and Focal Segmental Glomerulosclerosis (FSGS), which are both kidney diseases. The therapy being tested uses a drug called R3R01.

    The study aims to determine if R3R01 can improve kidney function and reduce damage in patients with these conditions. Participants will receive R3R01 for 12 weeks, and researchers will observe the changes in protein levels in their urine, kidney function, and any side effects. This study is designed to evaluate the safety, tolerability, and effectiveness of R3R01 in these patients.

    • R3R01
  • Study on the safety and effects of Vonafexor in patients with Alport Syndrome

    This study focuses on Alport syndrome, a genetic disorder affecting the kidneys. The therapy being tested is Vonafexor, a medication identified as EYP001a. The purpose of this study is to evaluate the safety of Vonafexor and its effects on kidney function in patients with Alport syndrome who are at risk of disease progression.

    The study involves a single group of patients who will receive escalating doses of Vonafexor over a 24-week treatment period, followed by a 12-week follow-up period. The main goals are to assess the safety of the drug and observe changes in kidney function and other renal biomarkers.

    • Vonafexor
  • Long-term safety and efficacy study of PTC518 for Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the long-term safety and effectiveness of the drug PTC518. Participants, who have previously completed related study phases, will continue taking PTC518 in doses of 5, 10, or 20 milligrams. The study aims to monitor the safety of long-term use and assess how the drug impacts biological markers and symptoms of the disease over a period of 30 months. This is an extension study where all participants will receive the active drug, ensuring continuous monitoring and evaluation of its effects.

    • PTC518
  • Study WVE-003 in patients with early-stage Huntington’s disease

    This clinical trial is a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug called WVE-003 in adult patients with early Huntington’s disease (HD). WVE-003 is a type of drug designed to target specific genetic sequences. In this case, it is targeting a single nucleotide polymorphism (SNP), known as SNP3, in Huntington’s disease patients. The drug is administered intrathecally, i.e., it is injected into the spinal canal.

    The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE-003 by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks.

    • WVE-003
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • Study of sarilumab in the treatment of juvenile idiopathic arthritis in children and adolescents

    This is a trial that aims to find the right dose of a drug called sarilumab for treating children and teenagers aged 1 to 17 years old with Systemic Juvenile Idiopathic Arthritis. Sarilumab is given as an injection under the skin. The main goal is to understand how the body processes this drug in young patients, so they can receive an adequate dose for treating their condition.

    The study will last for about 166 weeks, which is a little over 3 years. It starts with a 4-week screening period, followed by a 12-week treatment phase where the patients will receive repeated doses of sarilumab. After that, there is a 144-week extension phase where the patients can continue receiving the drug, and finally a 6-week follow-up period.

    During the first 12 weeks, the researchers will closely monitor the levels of sarilumab in the patients’ blood to understand how their bodies handle the drug. They will look at the maximum concentration reached, the total amount of drug exposure over time, and the levels just before each new dose. This information will help them determine the right dose and dosing schedule for children and adolescents with Systemic Juvenile Idiopathic Arthritis.

    In addition to studying the drug levels, the researchers will also evaluate the effectiveness of sarilumab in reducing the symptoms of this condition and monitor any potential side effects to ensure the drug is safe for long-term use in this age group.

    • Sarilumab
  • Isatuximab Plus Pomalidomide and Dexamethasone for AL Amyloidosis

    This clinical trial is focused on patients with AL Amyloidosis who have not achieved a very good partial response or better following previous therapies. The trial investigates the efficacy of combining Isatuximab, Pomalidomide, and Dexamethasone. The aim is to see if this drug combination can significantly reduce the levels of misfolded proteins in the blood, which are characteristic of this disease, thereby improving the condition and potentially prolonging life. This study seeks to offer a new potential treatment option for those who have limited responses to existing therapies.

    • Isatuximab

See more clinical trials in other cities in France:

.